Key result
Omega-3 Index above 8% is linked to high cardiovascular protection compared with deficient levels.
Why the study?
Clinical trials of long-chain omega-3 fatty acids have controversial results, potentially because most studies base findings on estimated intake rather than actual incorporation into tissue membranes.
Is the Omega-3 Index a reliable biomarker for predicting cardiometabolic risk and cardiovascular events?
Is the Omega-3 Index a reliable biomarker for predicting cardiometabolic risk and cardiovascular events?
The Omega-3 Index is a promising biomarker for cardiovascular risk stratification, with levels >8% indicating cardioprotection and <4% indicating high risk.
Introduction: Long-chain omega-3 fatty acids (EPA and DHA) have significant beneficial effects on cardiovascular health. However, there is considerable controversy regarding results of various clinical trials, that may be attributable to the fact that most studies are based on estimated intake, without determining the actual incorporation of omega-3 fatty acids into tissue membranes. The Omega-3 Index is the sum of percentages of EPA and DHA present in erythrocyte membranes, reflecting the nutritional status of these fatty acids in the heart and other organs. This paper reviews the evidence for the Omega-3 Index as a biomarker of cardiometabolic risk. Omega-3 Index values correlate better with cardioprotective effects than dietary questionnaires. Levels below 4 % are associated with a very high risk of cardiovascular events and sudden death, whilst values above 8 % are considered indicative of high cardiovascular protection. Thanks to its ability to predict all-cause mortality and the incidence of cardiometabolic diseases, it has been considered a new biomarker of cardiovascular risk, not only in research but also in clinical practice.
No takes yet. Share an insight, caveat, or question.
Mesa-García et al. (2026) conducted a review in Cardiometabolic risk. Omega-3 Index was evaluated. The Omega-3 Index is an emerging biomarker of cardiometabolic risk, where levels below 4% are associated with high risk of cardiovascular events and levels above 8% indicate high protection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: